ReviewMolecular cancer2020
Role of non-coding RNAs and RNA modifiers in cancer therapy resistance.
Review in Molecular cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 151 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
151 citing papers in PubMed, 6 syntheses or guidelines pooled it, 233 citations in OpenAlex.
- Multilevel Mechanisms of Cancer Drug Resistance.International journal of molecular sciences · 2024Pooled it
- Non-coding RNAs as modulators of radioresponse in triple-negative breast cancer: a systematic review.Journal of biomedical science · 2024Pooled it
- Non-coding RNAs in drug and radiation resistance of bone and soft-tissue sarcoma: a systematic review.eLife · 2022Pooled it
- LncRNAs as biomarkers for predicting radioresistance and survival in cancer: a meta-analysis.Scientific reports · 2022Pooled it
- Effects of noncoding RNAs in radiotherapy response in breast cancer: a systematic review.Cell cycle (Georgetown, Tex.) · 2022Pooled it
- Role of N6-Methyladenosine Methylation Regulators in the Drug Therapy of Digestive System Tumours.Frontiers in pharmacology · 2022Pooled it
- Therapeutic resistance in cancer: lncRNAs as modulators and targets for cancer therapy.Genes & diseases · 2026Review
- The role of STRA6 induced by ONECUT2 drives malignant progression and radioresistance in rectal cancer through activating the Wnt/β-Catenin signaling pathway.Molecular biology reports · 2026Article
- Losartan Enhances Radiosensitivity by Reversing Immunosuppressive Tumor Microenvironment Induced by Radiotherapy in TNBC.Cancer science · 2026Article
- Lnc1267-hnRNP U interaction promotes radioresistance by inhibiting apoptosis via attenuated RelA/p65 Ser536 phosphorylation.Cellular and molecular life sciences : CMLS · 2026Article
- A lncRNA and radiomics-based model for predicting the response of non-small cell lung cancer to chemo- and radio-therapy.Scientific reports · 2026Article
- Nanomaterials and exercise interventions: A synergistic approach for atherosclerosis therapy (Review).International journal of molecular medicine · 2026Review
- MTHFD2 is required for DNA repair and implicated in LUAD radiotherapy resistance.Journal of translational medicine · 2026Article
- Recent advances in novel targeting mechanisms for colorectal cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- MicroRNA-Mediated Regulation of Cancer Stem Cells: Implications for Radioresistance and Chemoresistance in Cancer Treatment.MicroRNA (Shariqah, United Arab Emirates) · 2026Review
- Drug resistance in cancer: molecular mechanisms and emerging treatment strategies.Molecular biomedicine · 2025Review
- lncRNA IGFL2-AS1 mediates NSCLC chemoresistance via YBX1-induced HSPA1A/RAP1 activation.Cellular & molecular biology letters · 2025Article
- Enhanced multi-omics analysis reveals a lncRNA signature with 12 RNA modifications to predict tumor heterogeneity and potential therapy in non-small cell lung cancer.Discover oncology · 2025Article
- Integrative multiomics analysis reveals the subtypes and key mechanisms of platinum resistance in gastric cancer: identification of KLF9 as a promising therapeutic target.Journal of translational medicine · 2025Article
- Tumor-associated macrophages-induced lncRNA RP11-627G18.1 promotes breast cancer metastasis.Genes and immunity · 2025Article
91 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As the standard treatments for cancer, chemotherapy and radiotherapy have been widely applied to clinical practice worldwide. However, the resistance to cancer therapies is a major challenge in clinics and scientific research, resulting in tumor recurrence and metastasis. The mechanisms of therapy resistance are complicated and result from multiple factors. Among them, non-coding RNAs (ncRNAs), along with their modifiers, have been investigated to play key roles in regulating tumor development and mediating therapy resistance within various cancers, such as hepatocellular carcinoma, breast cancer, lung cancer, gastric cancer, etc. In this review, we attempt to elucidate the mechanisms underlying ncRNA/modifier-modulated resistance to chemotherapy and radiotherapy, providing some therapeutic potential points for future cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.